&nbsp;

EmotionalandPsychologicalWell-beingforGyngecologicalCancerSurvivors.pdf

Jul 2024

Document

Emotional-and-Psychological-Well-being-Gynecological_FR.pdf

Jul 2024

Regimen

ENHE

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Drugs Used:

Enhertu trastuzumab deruxtecan (Unfunded)

Quick Link(s):

Regimen Monograph

May 2025

Regimen

GEMC+RAMU

Cancer Type:

Lung,

Mesothelioma (Pleural)

Intent: Palliative

Drugs Used:

ramucirumab (Unfunded),

gemcitabine

Quick Link(s):

Regimen Monograph

Oct 2024

Gestion de votre anxiété

Imprimer Ce guide destiné aux patients vous aidera à comprendre ce qui suit : Qu’est-ce que l’anxiété? Quelles peuvent être les sources d’...

Regimen

ENFO+PEMB

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer

New Drug Funding Program

Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer

Drugs Used:

enfortumab vedotin,

pembrolizumab

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

ENHE

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab Deruxtecan - Previously Treated Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Enhertu trastuzumab deruxtecan

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2025

Guidelines and Advice

Endometrial Cancer Molecular Testing Recommendations Report

Status: Current
Version: 1

Nov 2024

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Status: Current
ID: PET 2024-1

Mar 2025

Document

EndometrioidOvarianCancerTreatmentPathwayMap.pdf

Apr 2025

Document

E.1.50-CAR-TReferralWorksheet.pdf

New

May 2025

Regimen

GEMOX+GLOF

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Drugs Used:

oBINutuzumab (Unfunded),

gemcitabine,

oxaliplatin,

glofitamab (Unfunded)